Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 7/20 | 1.00 |
| ▸ | NR1H3 | Q13133 | 6/20 | 0.64 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.54 |
| ▸ | RORC | P51449 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3230674 | 0.88 | MLYCD (0.78) | MLYCDNR1H3MEN1KMT2AHDAC1 | |
| SCHEMBL5645193 | 0.87 | MEN1 (0.78) | MLYCDMEN1KMT2AHDAC1HDAC6 | |
| SCHEMBL4987436 | 0.86 | MLYCD (1.00) | MLYCDNR1H3NR1H2RORC | |
| SCHEMBL21923501 | 0.82 | MLYCD (0.70) | MLYCDMEN1KMT2AHDAC1HDAC6 | |
| SCHEMBL1003665 | 0.80 | KMT2A (0.83) | MLYCDMEN1KMT2AHDAC1HDAC6 | |
| SCHEMBL5644792 | 0.79 | LIMK2 (0.70) | MLYCDMEN1KMT2AHDAC1HDAC6 | |
| SCHEMBL2921609 | 0.77 | KMT2A (0.68) | MLYCDMEN1KMT2AHDAC1HDAC6 | |
| SCHEMBL3455399 | 0.77 | LIMK2 (0.69) | MLYCDMEN1KMT2AHDAC1HDAC6 | |
| SCHEMBL4628014 | 0.77 | NR1H3 (1.00) | MLYCDNR1H3NR1H2RORC | |
| SCHEMBL19630546 | 0.76 | KMT2A (0.66) | MLYCDMEN1KMT2AHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4503232-B2 | — | — | 2010-07-14 | — | — | JP | claimed |
| JP-2004521113-A | — | — | 2004-07-15 | — | — | JP | claimed |
| US-20040087627-A1 | Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-05-06 | — | — | US | claimed |
| EP-1353662-A2 | METHODS FOR THE TREATMENT OF DISEASES USING MALONYL-COA DECARBOX YLASE INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-10-22 | — | — | EP | claimed |
| WO-2002058690-A2 | METHODS FOR THE TREATMENT OF DISEASES USING MALONYL-COA DECARBOX YLASE INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-08-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087627-A1 | Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors | ME2, PC, ACACA | MLYCD 6/4885NR1H3 1227/4885NR1H2 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.